P53 expression, DNA ploidy and S-phase cell fraction in operable locally advanced non-small-cell lung cancer

被引:35
|
作者
Costa, A
Silvestrini, R
Mochen, C
Lequaglie, C
Boracchi, P
Faranda, A
Vessecchia, G
Ravasi, G
机构
[1] IST NAZL STUDIO & CURA TUMORI,I-20133 MILAN,ITALY
[2] UNIV MILAN,IST STAT MED & BIOMETRIA,I-20133 MILAN,ITALY
关键词
DNA ploidy; lung cancer; P53; expression; prognosis; H-3]thymidine labelling index;
D O I
10.1038/bjc.1996.163
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The identification of biomarkers to complement pathological stage for a more accurate prognosis and help clinicians decide on treatment is still an open problem for patients with lung cancer. Expression of P53 protein was detected by an immunohistochemical approach using the monoclonal antibody PAb1801 on paraffin-embedded sections of tumours obtained surgically from 102 stage II-IIIa patients with non-small-cell lung cancer (52 squamous cell carcinomas, 50 adenocarcinomas). [H-3]Thymidine labelling index, an indicator of the S-phase cell fraction, was evaluated on histological sections of [H-3]thymidine-labelled tumour samples. DNA ploidy was defined by flow cytometric analysis on frozen tumour tissue. The biomarkers, histology and pathological stage were analysed in relation to relapse-free survival in univariate and multivariate analyses. Stage and interaction between [H-3]thymidine labelling index and histology provided significant prognostic information for the overall series. [H-3]thymidine labelling index was an independent prognostic indicator of 3 year relapse-free survival in patients with adenocarcinoma. The results indicate the importance of cell proliferation to complement prognostic information provided by pathological stage in patients with stage II-IIIa adenocarcinomas.
引用
收藏
页码:914 / 919
页数:6
相关论文
共 50 条
  • [41] Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small-cell lung cancer
    M M Borner
    P Brousset
    B Pfanner-Meyer
    M Bacchi
    S Vonlanthen
    M A Hotz
    H J Altermatt
    D Schlaifer
    J C Reed
    D C Betticher
    British Journal of Cancer, 1999, 79 : 952 - 958
  • [42] Roles of Fhit and p53 in Taiwanese surgically treated non-small-cell lung cancers
    Chang, YL
    Wu, CT
    Shih, JY
    Lee, YC
    BRITISH JOURNAL OF CANCER, 2003, 89 (02) : 320 - 326
  • [43] DNA Ploidy and S-phase fraction, but not p53 or NM23-H1 expression, predict outcome in colorectal cancer patients.: Result of a 5-year prospective study
    Bazan, V
    Migliavacca, M
    Zanna, I
    Tubiolo, C
    Corsale, S
    Calò, V
    Amato, A
    Cammareri, P
    Latteri, F
    Grassi, N
    Fulfaro, F
    Porcasi, R
    Morello, V
    Nuara, RB
    Dardanoni, G
    Salerno, S
    Valerio, MR
    Dusonchet, L
    Gerbino, A
    Gebbia, N
    Tomasino, RM
    Russo, A
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2002, 128 (12) : 650 - 658
  • [44] Elevated transcription of the p53 gene in early S-phase leads to a rapid DNA-damage response during S-phase of the cell cycle
    Takahashi, Paula
    Polson, Amanda
    Reisman, David
    APOPTOSIS, 2011, 16 (09) : 950 - 958
  • [45] FHIT and p53 status and response to platinum-based treatment in advanced non-small cell lung cancer
    Cortinovis, D. L.
    Andriani, F.
    Livio, A.
    Fabbri, A.
    Perrone, F.
    Marcomini, B.
    Pilotti, S.
    Mariani, L.
    Bidoli, P.
    Bajetta, E.
    Roz, L.
    Sozzi, G.
    CURRENT CANCER DRUG TARGETS, 2008, 8 (05) : 342 - 348
  • [46] PROGNOSTIC-SIGNIFICANCE OF P53 PROTEIN EXPRESSION AND DNA-PLOIDY IN SURGICALLY TREATED NONSMALL CELL LUNG CARCINOMAS
    MORKVE, O
    HALVORSEN, OJ
    SKJAERVEN, R
    STANGELAND, L
    GULSVIK, A
    LAERUM, OD
    ANTICANCER RESEARCH, 1993, 13 (03) : 571 - 578
  • [47] Phase 2 Study of Nimotuzumab in Combination With Concurrent Chemoradiotherapy in Patients With Locally Advanced Non-Small-Cell Lung Cancer
    Yamamoto, Nobuyuki
    Harada, Hideyuki
    Okamoto, Isamu
    Masuda, Noriyuki
    Hayakawa, Kazushige
    Satouchi, Miyako
    Soejima, Toshinori
    Nishio, Makoto
    Kozuka, Takuyo
    Takeda, Koji
    Tanaka, Masahiro
    Seto, Takashi
    Sasaki, Tomonari
    Tsubouchi, Hiroshi
    Kakurai, Yasuyuki
    Nishimura, Yasumasa
    Nakagawa, Kazuhiko
    CLINICAL LUNG CANCER, 2021, 22 (02) : 134 - +
  • [48] Immunotherapy in advanced non-small-cell lung cancer withEGFRmutations
    Liu, Fangfang
    Yuan, Xun
    Jiang, Jizong
    Chu, Qian
    IMMUNOTHERAPY, 2020, 12 (16) : 1195 - 1207
  • [49] Concomitant radiochemotherapy of advanced non-small-cell lung cancer
    Fietkau, R
    LUNG CANCER, 2001, 33 : S65 - S76
  • [50] Prognostic evaluation of the expression of p53 and bcl-2 oncoproteins in patients with surgically resected non-small cell lung cancer
    Lai, RS
    Wang, JS
    Hsu, HK
    Chang, HC
    Lin, CH
    Lin, MH
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2002, 32 (10) : 393 - 397